Companies Dominating the Pulmonary Drug Delivery Systems Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Lupin Limited
- Briggs Healthcare, Inc.
- Boehringer Ingelheim International GmbH
- Koninklijke Philips N.V.
- Merck & Co., Inc.
- 3M Company
- AstraZeneca PLC
- GSK plc
- GF Health Products, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Pulmonary Drug Delivery Systems Market in 2025 is evaluated at USD 63.95 billion.
The global market size was worth around USD 60.56 billion in 2024 and is set to register a CAGR of more than 7%, exceeding USD 145.94 billion revenue by 2037.
North America is likely to approach majority share by 2037, driven by increasing prevalence of lung diseases and rising air pollution.
The major players in the market include Novartis AG, Lupin Limited, Briggs Healthcare, Inc., Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., Merck & Co., Inc., 3M Company, AstraZeneca PLC, GSK plc, GF Health Products, Inc.
